Circulating apoE4 protein levels from dried blood spots predict cognitive function in a large population-based survey settingShow others and affiliations
2024 (English)In: Alzheimer's & Dementia: Journal of the Alzheimer's Association, ISSN 1552-5260, E-ISSN 1552-5279, Vol. 20, no 11, p. 7613-7623Article in journal (Refereed) Published
Abstract [en]
INTRODUCTION: The apolipoprotein E (APOE) ε4 allele carries risk for cognitive impairment, but whether the level of circulating apoE4 protein in carriers affects cognition is unclear, as is how health and lifestyle impact circulating apoE4 levels.
METHODS: We assayed apoE4 protein levels in dried blood spots of 12,532 adults aged 50+. Regression analyses tested the likelihood of cognitive impairment between groups and within those with detected apoE4 protein. Predictors of circulating apoE4 were assessed.
RESULTS: We detected protein binding that indicates the presence of an APOE ε4 allele in 28.4% of this group. This group was more likely to have cognitive impairment, and this risk increases with age. However, higher apoE4 levels were associated with less likelihood of cognitive impairment within this group. Antihypertensive medication predicted apoE4 protein levels.
DISCUSSION: The apoE4 isoform is associated with a deficient protein and worse cognition. This association is modulated by the level of circulating apoE4 protein in ε4 carriers.
Place, publisher, year, edition, pages
John Wiley & Sons, 2024. Vol. 20, no 11, p. 7613-7623
Keywords [en]
APOE ε4 allele, apoE4 protein, cognition, dried blood spots, SHARE
National Category
Neurology
Identifiers
URN: urn:nbn:se:umu:diva-229627DOI: 10.1002/alz.14224ISI: 001307482300001PubMedID: 39234633Scopus ID: 2-s2.0-85203061070OAI: oai:DiVA.org:umu-229627DiVA, id: diva2:1898084
Funder
EU, Horizon 2020, ERC-STG-716065Max Planck SocietyEuropean Commission, QLK6-CT-2001-00360EU Sixth Framework Programme for Research, SHARE-I3: RII-CT-2006-062193EU Sixth Framework Programme for Research, COMPARE: CIT5-CT- 2005-028857EU Sixth Framework Programme for Research, SHARELIFE: CIT4-CT-2006-028812EU, FP7, Seventh Framework Programme, SHARE-PREP: GA N◦211909EU, FP7, Seventh Framework Programme, SHARE-LEAP: GA N◦227822EU, FP7, Seventh Framework Programme, SHARE M4: GA N◦261982EU, FP7, Seventh Framework Programme, DASISH: GA N◦283646EU, Horizon 2020, SHARE-DEV3: GA N◦676536EU, Horizon 2020, SHARE-COHESION: GA N◦870628EU, Horizon 2020, SERISS: GA N◦654221EU, Horizon 2020, SSHOC: GA N◦8237822024-09-162024-09-162024-12-06Bibliographically approved